BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q4 2022 vs. Q3 2022
How the institutions holding BIO-TECHNE Corp changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 536 | 7 | 547 | +18 |
| SharesConverted for a 4-for-1 split | 152.0M | 2.08M | 149.8M | −84.0K (−0.1%) |
| Value | $10.8B | $147.6M | $12.4B | +$1.77B (+16.6%) |
7 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (77)
Institutions that held BIO-TECHNE Corp at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (59)
Institutions that held BIO-TECHNE Corp at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (7)
Institutions that held BIO-TECHNE Corp at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Atlanta Capital Management Co L L C | 472,491 | $134.2M |
| Eaton Vance Management | 39,312 | $11.2M |
| Corient Capital Partners, LLC | 3,141 | $1.09M |
| American Portfolios Advisors | 1,513 | $429.7K |
| Regentatlantic Capital LLC | 1,128 | $320.0K |
| Redpoint Investment Management Pty Ltd | 950 | $270.0K |
| Wipfli Financial Advisors LLC, | 526 | $149.0K |